Janssen’s human trials for dengue virus to advance to phase II
Janssen Pharmaceutical Companies, a wholly-owned subsidiary of Johnson & Johnson, announced its first-in-human clinical trial of a compound to treat dengue had entered.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Janssen Pharmaceutical Companies, a wholly-owned subsidiary of Johnson & Johnson, announced its first-in-human clinical trial of a compound to treat dengue had entered.
he WHO has identified 55 nations vulnerable to a shortfall in health workers needed to fulfil the UN’s charter for universal health coverage.
The FDA cleared the emergency use of bivalent Pfizer-Biotech COVID-19 vaccine for a single dose booster in children aged six months to four.
Denmark's Novo Nordisk plans to effect a 75% cut in insulin prices in the U.S. market by January 1, 2024.
Sanofi acquires Provention Bio, and its TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).
Pfizer will acquire Seagen for $43 billion to beef up its cancer portfolio, with COVID-19 vaccine sales forecast to plummet.
Merck announced its experimental trial on patients with pulmonary arterial hypertension had led to an extension in walking distance and reduced exacerbating the.
The Indian government and the World Bank signed two agreements to support and enhance the development of the health sector in the south.
A probe by the US-based Centres for Disease Control into the deaths of 70 children in Gambia "strongly suggests" cough syrups involving contaminated.
Cytokinetics, a US-based biopharmaceutical company, announced the FDA had rejected its new drug application for approving a trial drug to treat heart problems.